title: Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.
abstract: Biomarkers of blood lipid modification and oxidative stress have been associated with increased cardiovascular morbidity. We sought to determine whether these biomarkers were related to functional indices of stenosis severity among patients with stable coronary artery disease. We studied 197 consecutive patients with stable coronary artery disease due to single vessel disease. Fractional flow reserve (FFR) ≤ 0.80 was assessed as index of a functionally significant lesion. Serum levels of secretory phospholipase A2 (sPLA2) activity, secretory phospholipase A2 type IIA (sPLA2-IIA), myeloperoxydase (MPO), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidized low-density lipoprotein (OxLDL) were assessed using commercially available assays. Patients with FFR > 0.8 had higher sPLA2 activity, sPLA2 IIA, and OxLDL levels than patients with FFR ≤ 0.8 (21.25 [16.03-27.28] vs 25.85 [20.58-34.63] U/mL, p < 0.001, 2.0 [1.5-3.4] vs 2.6 [2.0-3.4] ng/mL, p < 0.01; and 53.0 [36.0-71.0] vs 64.5 [50-89.25], p < 0.001 respectively). Patients with FFR > 0.80 had similar Lp-PLA2 and MPO levels versus those with FFR ≤ 0.8. sPLA2 activity, sPLA2 IIA significantly increased area under the curve over baseline characteristics to predict FFR ≤ 0.8 (0.67 to 0.77 (95 % confidence interval [CI]: 0.69-0.85) p < 0.01 and 0.67 to 0.77 (95 % CI: 0.69-0.84) p < 0.01, respectively). Serum sPLA2 activity as well as sPLA2-IIA level is related to functional characteristics of coronary stenoses in patients with stable coronary artery disease.
authors.affiliation: Cardiovascular Center and Translational Cardiology Unit, Aalst, Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Muller
authors.forename: Argyrios
authors.initials: A
authors.lastname: Ntalianis
authors.forename: William
authors.initials: W
authors.lastname: Wijns
authors.forename: Leen
authors.initials: L
authors.lastname: Delrue
authors.forename: Karen
authors.initials: K
authors.lastname: Dierickx
authors.forename: Reto
authors.initials: R
authors.lastname: Auer
authors.forename: Nicolas
authors.initials: N
authors.lastname: Rodondi
authors.forename: Fabio
authors.initials: F
authors.lastname: Mangiacapra
authors.forename: Catalina
authors.initials: C
authors.lastname: Trana
authors.forename: Michalis
authors.initials: M
authors.lastname: Hamilos
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Valentin
authors.forename: Bernard
authors.initials: B
authors.lastname: De Bruyne
authors.forename: Emanuele
authors.initials: E
authors.lastname: Barbato
authors.forename: Jozef
authors.initials: J
authors.lastname: Bartunek
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D000368:Aged; D015415:Biomarkers / Q000097:blood; D006328:Cardiac Catheterization; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D023921:Coronary Stenosis / Q000097:blood* / Q000503:physiopathology; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D053805:Fractional Flow Reserve, Myocardial; D054501:Group II Phospholipases A2 / Q000097:blood; D006801:Humans; D016014:Linear Models; D050356:Lipid Metabolism; D008077:Lipoproteins, LDL / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D009195:Peroxidase / Q000097:blood; D058226:Plaque, Atherosclerotic; D011237:Predictive Value of Tests; D011379:Prognosis; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D009195:Peroxidase; D054501:Group II Phospholipases A2; C516287:PLA2G2A protein, human; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase